AU2014225575A8 - Individualized high purity hepatocellular carcinoma stem cells, methods and use of the same - Google Patents
Individualized high purity hepatocellular carcinoma stem cells, methods and use of the sameInfo
- Publication number
- AU2014225575A8 AU2014225575A8 AU2014225575A AU2014225575A AU2014225575A8 AU 2014225575 A8 AU2014225575 A8 AU 2014225575A8 AU 2014225575 A AU2014225575 A AU 2014225575A AU 2014225575 A AU2014225575 A AU 2014225575A AU 2014225575 A8 AU2014225575 A8 AU 2014225575A8
- Authority
- AU
- Australia
- Prior art keywords
- stem cells
- methods
- hepatocellular carcinoma
- same
- high purity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010073071 hepatocellular carcinoma Diseases 0.000 title abstract 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 title abstract 3
- 210000000130 stem cell Anatomy 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 3
- 230000028993 immune response Effects 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/13—Tumour cells, irrespective of tissue of origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
- C12N5/0695—Stem cells; Progenitor cells; Precursor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/53—Liver
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The disclosure provides cancer stem cells, for use in stimulating immune response against a cancer, such as hepatocellular carcinoma (HCC). Methods for preparing and purifying the cancer stem cells are provided.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361774517P | 2013-03-07 | 2013-03-07 | |
US61/774,517 | 2013-03-07 | ||
AUPCT/US2013/053850 | 2013-08-06 | ||
PCT/US2013/053850 WO2014028274A1 (en) | 2012-08-15 | 2013-08-06 | Rapid method production high purity cancer stem cells and population of high purity cancer stem cells |
PCT/US2014/021353 WO2014138455A1 (en) | 2013-03-07 | 2014-03-06 | Individualized high purity hepatocellular carcinoma stem cells, methods and use of the same |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2014225575A1 AU2014225575A1 (en) | 2015-09-10 |
AU2014225575A8 true AU2014225575A8 (en) | 2015-10-01 |
Family
ID=51491971
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2014225575A Abandoned AU2014225575A1 (en) | 2013-03-07 | 2014-03-06 | Individualized high purity hepatocellular carcinoma stem cells, methods and use of the same |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP2964754A4 (en) |
JP (1) | JP2016510756A (en) |
KR (1) | KR20150139855A (en) |
CN (1) | CN105308177A (en) |
AU (1) | AU2014225575A1 (en) |
CA (1) | CA2903212A1 (en) |
WO (1) | WO2014138455A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI563085B (en) * | 2014-08-29 | 2016-12-21 | China Medidal University Hospital | Dendritic cell tumor vaccine and preparation method thereof |
WO2016048872A1 (en) * | 2014-09-23 | 2016-03-31 | Neostem Oncology, Llc | Compositions, methods and kits used to determine potency of dendritic cells in cancer immunitherpay |
CN105031632B (en) * | 2015-06-16 | 2018-08-10 | 杭州优善生物科技有限公司 | A kind of dendritic cell vaccine and the preparation method and application thereof |
KR101634546B1 (en) | 2015-10-05 | 2016-06-29 | 주식회사 현대케피코 | Apparatus for controlling electronic continuously variable valve timing and method thereof |
US20180355321A1 (en) * | 2015-12-18 | 2018-12-13 | Zeon Corporation | Method for preparing adherent-type cells acclimated to suspension culture, method for inducing epithelial-mesenchymal transition in adherent-type epithelial cells, and use for methods |
JP2019511919A (en) * | 2016-02-23 | 2019-05-09 | ブローディ,チャヤ | Production of cancer stem cells and use thereof |
CN106636366A (en) * | 2016-11-25 | 2017-05-10 | 苏州首度基因科技有限责任公司 | Gene detection kit for prognosing gastric cancer metastasis and use method of gene detection kit |
KR101869518B1 (en) * | 2018-03-28 | 2018-06-20 | 황인후 | Method of Preparing Dendritic Cell Based Cancer Vaccine Using EMT-MET Plasticity in Pancreatic Cancer Stem Cells |
CN111733136B (en) * | 2020-06-29 | 2021-11-30 | 中山大学孙逸仙纪念医院 | Method for improving separation efficiency of CD90posi cells |
CN111909962A (en) * | 2020-07-23 | 2020-11-10 | 药鼎(北京)国际细胞医学技术有限公司 | Virus construct for treating liver cancer and application and construction method thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110244501A1 (en) * | 2006-08-02 | 2011-10-06 | Biogen Idec Ma Inc. | Cancer stem cells |
US8129184B2 (en) * | 2006-09-26 | 2012-03-06 | Cedars-Sinai Medical Center | Cancer stem cell antigen vaccines and methods |
WO2010011893A1 (en) * | 2008-07-24 | 2010-01-28 | University Of Central Florida Research Foundation, Inc. | Therapy targeting cancer stem cells |
ES2711504T3 (en) * | 2009-07-24 | 2019-05-06 | Rhode Island Hospital | Dendritic cell vaccines for tumors that express asparaginyl-beta-hydroxylase |
CN102793912A (en) * | 2011-05-26 | 2012-11-28 | 北京清美联创干细胞科技有限公司 | Dendritic cell (DC) tumor vaccine and preparation method thereof |
-
2014
- 2014-03-06 WO PCT/US2014/021353 patent/WO2014138455A1/en active Application Filing
- 2014-03-06 JP JP2015561670A patent/JP2016510756A/en not_active Abandoned
- 2014-03-06 KR KR1020157027990A patent/KR20150139855A/en not_active Application Discontinuation
- 2014-03-06 AU AU2014225575A patent/AU2014225575A1/en not_active Abandoned
- 2014-03-06 EP EP14760978.8A patent/EP2964754A4/en not_active Withdrawn
- 2014-03-06 CN CN201480025747.0A patent/CN105308177A/en active Pending
- 2014-03-06 CA CA2903212A patent/CA2903212A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN105308177A (en) | 2016-02-03 |
KR20150139855A (en) | 2015-12-14 |
AU2014225575A1 (en) | 2015-09-10 |
WO2014138455A1 (en) | 2014-09-12 |
JP2016510756A (en) | 2016-04-11 |
CA2903212A1 (en) | 2014-09-12 |
EP2964754A1 (en) | 2016-01-13 |
EP2964754A4 (en) | 2016-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2014225575A8 (en) | Individualized high purity hepatocellular carcinoma stem cells, methods and use of the same | |
HK1222121A1 (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc ( nsclc ) | |
PH12017500022A1 (en) | Carrier-antibody compositions and methods of making and using the same | |
IN2014CN03143A (en) | ||
MX366804B (en) | R-spondin translocations and methods using the same. | |
MX2013008390A (en) | Preparation of metal-triazolate frameworks. | |
AU2014249346A8 (en) | High purity ovarian cancer stem cells for active autologous immune therapy | |
MX2015009106A (en) | Solid solution compositions and use in severe pain. | |
MX2015014431A (en) | Gla monotherapy for use in cancer treatment. | |
PH12015500040A1 (en) | Supercritical hydrolysis of biomass | |
MX2016014235A (en) | Microbial ergothioneine biosynthesis. | |
MX2020010991A (en) | Composition for controlled ovarian stimulation. | |
EP3641789A4 (en) | Methods for producing regulatory immune cells and uses thereof | |
MX2016003653A (en) | Papaya mosaic virus and virus-like particles in cancer therapy. | |
IN2014DN06104A (en) | ||
MY191539A (en) | Streptococcal vaccine | |
EP3016936A4 (en) | Process for preparing clomazone, novel form and use of the same | |
WO2014197835A3 (en) | Methods and compositions for the treatment of cancer | |
IL246143A0 (en) | Acid-solubilized copper-ammonium complexes and copper-zinc-ammonium complexes, compositions, preparations, methods, and uses | |
EP3086360A4 (en) | Semiconductor element, method for producing same and aliphatic polycarbonate | |
MX357675B (en) | Anti-jagged anitbodies and methods of use. | |
IN2014MU00455A (en) | ||
MX2015010023A (en) | Anti-cd83 antibodies and use thereof. | |
EP3030268A4 (en) | Combination of ifn-gamma with anti-erbb antibody for the treatment of cancers | |
AU2016204389A1 (en) | Kinase inhibitors for the treatment of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TH | Corrigenda |
Free format text: IN VOL 29 , NO 35 , PAGE(S) 5305 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME NEOSTEM ONCOLOGY, LLC, APPLICATION NO. 2014225575, UNDER INID (72) CORRECT THE CO-INVENTOR TO NISTOR, GABRIEL |
|
MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |